Recents
Developing an educational resource on DDAVP for persons with bleeding disorders
Desmopressin, or DDAVP, plays a crucial role in the treatment of persons with inherited bleeding disorders, including von Willebrand disease,…
Contaminated blood: exploring the intergenerational impact
There is much to say about the contaminated blood scandal of the 1970s and ‘80s. It devastated the bleeding disorders…
Gene therapy for haemophilia B in the UK? Hold your horses!
After years on the track, gene therapy for haemophilia seems to have the home straights firmly in sight. Products for…
Animating self-advocacy for the bleeding disorders community
If you live with a bleeding disorder, self-advocacy isn’t just important – it’s vital. As a group of people who…
Improving joint health assessment when resources are limited
A recent paper in The Journal of Haemophilia Practice by Bhabani Sankar Dhal and colleagues describes the importance of regular…
Reflections from the Glanzmann’s Research Foundation Inaugural Patient Conference
Last week, Kate and I hopped over the pond to attend the Glanzmann’s Research Foundation’s (GRF) first ever educational conference…
Hub and spoke – not just about bicycles
Last year, the first gene therapy to treat severe haemophilia A was granted ‘conditional marketing authorisation’ in Europe (basically, fast-track…
All go for Haemnet at ISTH 2023
The International Society for Thrombosis and Haemostasis (ISTH) is an organisation of clinicians and scientists sharing new discoveries, enhanced understanding…
A natural history of haemophilia treatments
In a recent paper in The Journal of Haemophilia Practice, Tyler Buckner and colleagues describe the development of ‘ATHN 7’.…
A good year for The Journal of Haemophilia Practice
There is always a sense of anticipation among Haemnet’s publications team when we receive the annual report for The Journal…
Reflecting on the role of the haemophilia nurse
For International Nurses Day 2023, I’m delighted that The Journal of Haemophilia Practice is publishing the first papers in our Living,…
Mild disorders matter
People whose bleeding disorders are categorised as ‘mild’ (often defined as having between 5% to 40% of usual clotting levels)…